OOIR: Observatory of International Research

Papers

(The H4-Index of American Journal of Psychiatry is 49. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
Treating Pathologies of the Will	246
Evaluating Associations Between Cannabis and Heroin Use	194
Broadening the Parameters of Clinical High Risk for Psychosis	170
2024 Annual Meeting: Presidential Address	159
From Scanner to Bedside: Building Bridges in Translational Psychiatric Neuroimaging	154
From Prediction to Action: Moving Beyond Machine Learning to Implementing Evidence-Based Perinatal Mental Health Care	148
Predicting Conversion to Psychosis: What Lies Beyond the Biomarkers?	144
Updates and Advances in the Treatment of Substance Use Disorders, Depression, and Borderline Personality Disorder	132
Can Neuromelanin-Sensitive MRI Provide Insight Into the Dopaminergic Pathways Contributing to Substance Use?	123
Mental Health Disparities Research: An Introduction to New Directions	118
Reconsidering the Interpretive Basis of Neural Efficiency as a Biomarker in Pediatric Anxiety: Response to Ai and Colleagues	113
Depression, Inflammation, and Postpartum Psychosis	111
Neuroplasticity, Antipsychotic Efficacy, Schizophrenia Risk Reduction With Doxycycline Exposure, and Cannabis and Alcohol Use Interactions	109
Effectiveness of Antipsychotic Use for Reducing Risk of Work Disability: Results From a Within-Subject Analysis of a Swedish National Cohort of 21,551 Patients With First-Episode Nonaffective Psychosi	101
Neural Signatures of Pain Modulation in Short-Term and Long-Term Mindfulness Training: A Randomized Active-Control Trial	100
Future of Sensorimotor and Psychomotor Dysfunction in Mental Disorders: Emerging Tools, Methodological Challenges, and the Road Ahead	98
A Call to Psychiatrists: Deprescription of Unnecessary Anticholinergic Medications in Schizophrenia Must Start Now	94
A New Agenda for Optimizing Investments in Community Mental Health and Reducing Disparities	94
Project Harmony: A Meta-Analysis With Individual Patient Data on Behavioral and Pharmacologic Trials for Comorbid Posttraumatic Stress and Alcohol or Other Drug Use Disorders	82
Correcting Overestimations in Self-Harm Visit Data	80
An Innovative Approach to Extending the Antidepressant Effects of Intravenous Ketamine in Major Depression	78
Methamphetamine-Induced Psychosis and Schizophrenia: A Call for Special Attention: Response to Zhu et al.	78
Correction to Poirot et al.	76
Corrigendum to Morley et al.	75
Schizophrenia Imaging Signatures and Their Associations With Cognition, Psychopathology, and Genetics in the General Population	74

Reduced Brain Responsiveness to Emotional Stimuli With Escitalopram But Not Psilocybin Therapy for Depression	73
Older Adults are at Heightened Risk of the Effects of Cannabis Use: Response to Walaszek	71
2024 Annual Meeting: CEO and Medical Director’s Address	71
The First Large GWAS Meta-Analysis for Postpartum Depression	69
12-month Prevalence Estimates of Substance Use Disorders Using DSM-5 Versus DSM-IV Criteria Among U.S. Nonelderly Adults With Substance Use	69
Highlights From the Residents’ Journal: September 2024	66
Sensitivity of Schizophrenia Endophenotype Biomarkers to Anticholinergic Medication Burden	66
Suicide and the Menstrual Cycle	63
Highlights From the Residents’ Journal: March 2026	62
Sex Differences in Psychiatric Comorbidity Among Adults With Substance Use Disorders	62
Reduced Threat-Related Neural Efficiency: A Possible Biomarker for Pediatric Anxiety Disorders	60
Durability of Effects of Cognitive Remediation on Cognition and Psychosocial Functioning in Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Clinical Trials	60
Neural Responses to Intranasal Oxytocin in Youths With Severe Irritability	59
Primary Prevention of PTSD Symptoms in Combat-Deploying Soldiers Using Attention Bias Modification: A Randomized Controlled Trial	58
New Insights Into Psychotic Disorders	56
Trends in Prescription Stimulant, Opioid, and Benzodiazepine Use and Diversion in U.S. Adolescents	54
Familial Risk of Postpartum Psychosis	53
Similar Rates of Deleterious Copy Number Variants in Early-Onset Psychosis and Autism Spectrum Disorder	53
Characterizing the Most Vulnerable Prefrontal Cortical Neurons in Schizophrenia	53
Toward Inclusive, Evidence-Based rTMS Care for Patients With Co-Occurring Substance Use Disorders: Response to Steele et al.	52
Beyond Symptom Thresholds: Toward a Clinically and Culturally Inclusive Definition of Relapse in Schizophrenia	52
Scientific Advances Relevant to Schizophrenia, Psychosis, and the Treatment of Methamphetamine Use Disorder	52
Smoking Cessation Treatment: Still Seeking a New Approach?	51
Points that Need Attention in Early Auditory Information Processing Research in Schizophrenia: Response to Lin and Hsieh	50
Associations Between a Primary Care-Delivered Alcohol-Related Brief Intervention and Subsequent Opioid-Related Outcomes	49
Rebecca W. Brendel, M.D., J.D., 149th President, 2022–2023	49